Strategic Intelligence & Payer Engagement
AI-driven insights for reimbursement strategy, HTA navigation, payer communication, and competitive positioning — across NICE, G-BA, HAS, ICER, CADTH, AIFA, and AEM.
Real-time intelligence across global HTA bodies
Live HTA Intelligence
- Queries HTA reports from NICE, G-BA, HAS, ICER, CADTH, AIFA, AEM in original language
- Summarizes HTA committee rationale, evidence critiques, and comparator decisions
- Tracks evolving HTA guidance and policy shifts across markets
- Identifies early access risk signals for pipeline assets
Multi-Country Coverage Mapping
- Automated multi-country reimbursement landscape in 48 hours
- Maps coverage, formulary placement, and access restrictions by country
- Benchmarks pricing against comparable agents in same class
- Generates executive summaries per disease area and geography
Outcomes Monitoring
- Monitors competitor HTA outcomes and reimbursement decisions in real time
- Tracks ICER assessments for biosimilars and novel agents
- Identifies competitor evidence gaps to leverage in value arguments
- Builds positioning maps across clinical, economic, and humanistic dimensions
Payer Strategy, Value Messaging & Objection Handling
Payer Value Story Generation
Crafts data-driven value narratives for specific payer audiences — integrating clinical differentiation, economic offsets, and humanistic outcomes aligned with payer decision criteria.
Objection Handler Development
Identifies anticipated payer objections based on prior HTA decisions, then generates structured Q&A documents with counterarguments on durability, effectiveness, and pricing.
Payer Briefing Notes
Auto-generates concise 1–2 page briefing notes synthesizing clinical evidence, budget impact, and access context — ready for field teams to use in payer meetings.
Additional Capabilities
End-to-end support across the payer engagement lifecycle — from early scheme design to RWE-backed negotiations.
- Patient access scheme modeling
- Outcomes-based contract framing
- Country-specific dossier narratives
- AMNOG added-benefit argumentation
- Patient advocacy alignment analysis
- Coverage with evidence development
- RWE for payer negotiation
- Multi-stakeholder objection simulation
Submission-ready content across markets
HTA Dossier Writing Assistance
Generates structured draft content for value dossiers — clinical summaries, PICOTS, evidence tables, economic model narrative, and appendices — aligned to each HTA body's submission template. Accelerates authoring for NICE, G-BA, CADTH, and ICER submissions.
Multi-Country Model Adaptation
Adapts global health-economic models to local requirements — adjusting unit costs, epidemiology, comparators, and discount rates for France, Germany, Italy, Spain, UK, Canada, and US. Generates localized model narratives aligned with local HTA methodology.
Budget Impact Analysis
Estimates payer-specific budget impact accounting for formulary dynamics, patient share, real-world adherence, and cost offsets — across commercial, Medicare, and Medicaid populations.
Early Value Scoping
Identifies key drivers of value at Phase II — enabling early pricing and market access strategy, evidence gap analysis, and Phase III trial design optimization.
Affordability & Access Modeling
Models patient access schemes, managed entry agreements, and risk-sharing contracts to support reimbursement negotiations with payers and HTA bodies.
Markets Covered Natively
US, UK, Germany, France, Italy, Spain, Canada, Australia, China and Japan — with multilingual ingestion and English-language synthesis.
Win the Payer Conversation
Translate evidence into payer-ready narratives, dossiers, and objection handlers — in days, not months.
Request a Demo